| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |